厄贝沙坦氢氯噻嗪片联和伲福达治疗高血压的疗效观察  

Efficacy of Irbesartan Hydrochlorothiazide Tablets Combined with Niforda in the Treatment of Hypertension

作　　者：孙冠军 SUN Guan-jun(Department of Internal Medicine,Suining Rehabilitation Hospital,Suining,Jiangsu Province,221200,China)

机构地区：[1]睢宁康复医院内科

出　　处：《中外医疗》2019年第34期83-85,共3页China & Foreign Medical Treatment

摘　　要：目的分析高血压患者采用厄贝沙坦氢氯噻嗪联合伲福达治疗的临床应用价值。方法方便选择2017年1月—2019年5月该院心内科收治高血压患者60例为研究对象,根据患者入院先后顺序将其分为观察组与对照组,对照组30例患者均单纯采用厄贝沙坦氢氯噻嗪片治疗,观察组30例患者采用厄贝沙坦氢氯噻嗪联合伲福达治疗,比较两组患者治疗效果,检测并分析各组患者治疗前后血压指标及生化指标差异,记录并计算各组患者不良反应总发生率。结果观察组患者临床总有效率(96.67%)明显高于对照组(χ^2=7.68,P<0.05)。两组患者未用药治疗前血压指标、生化指标差异无统计学意义(P>0.05),经治疗后,观察组患者收缩压(129.48±5.66)mmHg、舒张压(80.49±2.01)mmHg、C反应蛋白(14.59±0.47)mg/L、白介素-6(5.35±0.38)pg/mL均明显低于对照组(t=18.16、14.81、16.55、12.49,P<0.05)。观察组患者不良反应总发生率(10.00%)与对照组对比差异无统计学意义(χ^2=0.22,P>0.05)。结论高血压患者采用厄贝沙坦氢氯噻嗪联合伲福达治疗效果更佳,可改善患者血压指标及生化指标,安全性高,值得临床应用推广。Objective To analyze the clinical application value of irbesartan hydrochlorothiazide combined with niforda in patients with hypertension.Methods Convenient select from January 2017 to May 2019 in our heart treated hypertensive patients with 60 cases as the research object,according to the patients admitted to hospital order will be divided into observation group and control group,30 patients in the control group were treated with irbesartan hydrochlorothiazide tablet alone,30 patients in the observation group were treated with irbesartan hydrochlorothiazide combined with niforda,compared two groups of patients with the treatment effect,to detect and analyze each group before and after treatment in patients with blood pressure index and biochemical index differences,record and calculate the incidence of adverse reactions always groups of patients.Results The total clinical effective rate(96.67%)of the observation group was significantly higher than that of the control group(χ^2=7.68,P<0.05).There was no statistically significant difference in blood pressure and biochemical indexes between the two groups before treatment.After treatment,systolic blood pressure(129.48±5.66)mmHg,diastolic blood pressure(80.49±2.01)mmHg,c-reactive protein(14.59±0.47)mg/L,interleukin-6(5.35±0.38)pg/mL in the observation group were significantly lower than those in the control group(t=18.16,14.81,16.55,12.49,P<0.05).The total incidence of adverse reactions in the observation group(10.00%)was not statistically significantly different from that in the control group(χ^2=0.22,P>0.05).Conclusion Irbesartan hydrochlorothiazide combined with Nefoda has better therapeutic effect in patients with hypertension.It can improve blood pressure and biochemical indexes of patients with hypertension.It is safe and worthy of clinical application and promotion.

关 键 词：厄贝沙坦氢氯噻嗪 伲福达 高血压 舒张压 收缩压 

分 类 号：R544[医药卫生—心血管疾病]